172 related articles for article (PubMed ID: 14654935)
1. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
Kim R; Emi M; Tanabe K; Toge T
Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
4. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
[TBL] [Abstract][Full Text] [Related]
5. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
6. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.
Del Bufalo D; Trisciuoglio D; Scarsella M; Zangemeister-Wittke U; Zupi G
Oncogene; 2003 Nov; 22(52):8441-7. PubMed ID: 14627985
[TBL] [Abstract][Full Text] [Related]
7. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
Kim R; Emi M; Matsuura K; Tanabe K
Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
[TBL] [Abstract][Full Text] [Related]
8. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 family members as molecular targets in cancer therapy.
Marzo I; Naval J
Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
11. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
Herbst RS; Frankel SR
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
[TBL] [Abstract][Full Text] [Related]
12. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
13. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 antisense therapy in B-cell malignancies.
Chanan-Khan A
Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
[TBL] [Abstract][Full Text] [Related]
15. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
Olie RA; Zangemeister-Wittke U
Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
19. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of angiogenesis by antisense oligonucleotides to clusterin.
Jackson JK; Gleave ME; Gleave J; Burt HM
Angiogenesis; 2005; 8(3):229-38. PubMed ID: 16308731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]